Adamis Pharma Stock Gains On Resubmission Of Zimhi US Application For Opioid Overdose

Adamis Pharmaceuticals Corporation ADMP has resubmitted a marketing application to the FDA for Zimhi, a naloxone injection product candidate intended to treat opioid overdose.
"Based on FDA feedback received during our Type A meeting in April, we have resubmitted our NDA for ZIMHI, which I am confident fully addresses the issues raised in the Complete Response Letter," said President and CEO Dr. Dennis J. Carlo.
In November last year, the company received a CRL. The FDA questions were generally related to new Chemistry, Manufacturing, and Controls issues.
Price Action: ADMP shares are trading 4.02% higher at $0.74 on the last check Monday.

Posted In:

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.